Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Gurney, S. Ackland, V. Gebski, G. Farrell (1998)
Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 7
S. Rodenhuis, M. Bontelbal, L. Beex (2000)
Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary nodes [abstract 286]
Paula Poikonen, T. Saarto, J. Lundin, H. Joensuu, C. Blomqvist (1999)
Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMFBritish Journal of Cancer, 80
M. Levine, V. Bramwell, K. Pritchard, B. Norris, L. Shepherd, H. Abu‐Zahra, B. Findlay, D. Warr, D. Bowman, J. Myles, A. Arnold, T. Vandenberg, R. Mackenzie, J. Robert, J. Ottaway, M. Burnell, C. Williams, D. Tu (1998)
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 8
G. Hortobagyi (1999)
High-dose chemotherapy for primary breast cancer: facts versus anecdotes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 11 Suppl
W. Hryniuk, E. Frei, F Wright (1998)
A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 9
L. Norton (1997)
Evolving concepts in the systemic drug therapy of breast cancer.Seminars in oncology, 24 4 Suppl 10
J. Bergh (2000)
Where next with stem-cell-supported high-dose therapy for breast cancer?The Lancet, 355
(2001)
Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trialJ Clin Oncol, 19
M. Gascon, P. Dayer (1991)
Oxford textbook of clinical hepatology
G. Bonadonna, P. Valagussa (1981)
Dose-response effect of adjuvant chemotherapy in breast cancer.The New England journal of medicine, 304 1
D. Budman, D. Berry, C. Cirrincione, I. Henderson, W. Wood, R. Weiss, C. Ferree, H. Muss, M. Green, L. Norton, E. Frei (1998)
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.Journal of the National Cancer Institute, 90 16
W. Wood, D. Budman, A. Korzun (1994)
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma [published erratum appears in N Engl J Med 1994; 331:139]N Engl J Med, 330
G. Koren, Kim Beatty, Arnold Seto, T. Einarson, M. Lishner (1992)
The Effects of Impaired Liver Function on the Elimination of Antineoplastic AgentsAnnals of Pharmacotherapy, 26
Early Group (1992)
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 womenThe Lancet, 339
E. Stadtmauer, A. O'neill, Lori Goldstein, Pamela Crilley, Kenneth Mangan, James Ingle, I. Brodsky, S. Martino, H. Lazarus, J. Erban, C. Sickles, John Glick (2000)
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.The New England journal of medicine, 342 15
S. Rodenhuis, D. Richel, E. Wall, J. Schornagel, J. Baars, C. Koning, J. Peterse, J. Borger, W. Nooijen, R. Bakx, O. Dalesio, E. Rutgers (1998)
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvementThe Lancet, 352
K. Antman, P. Rowlings, W. Vaughan, C. Pelz, J. Fay, K. Fields, C. Freytes, R. Gale, B. Hillner, H. Holland, M. Kennedy, J. Klein, H. Lazarus, P. McCarthy, R. Saez, G. Spitzer, E. Stadtmauer, S. Williams, S. Wolff, K. Sobocinski, J. Armitage, M. Horowitz (1997)
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 5
J. Bergh, T. Wiklund, B. Erikstein (2000)
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for highrisk breast cancer: a randomised trial. Scandinavian Breast Group 9401 studyLancet, 356
Louise Crochow, C. Baraldi, D. Noe (1990)
Is dose normalization to weight or body surface area useful in adults?Journal of the National Cancer Institute, 82 4
M. Colleoni, K. Price, M. Castiglione‐Gertsch, A. Goldhirsch, A. Coates, J. Lindtner, J. Collins, R. Gelber, B. Thürlimann, C. Rudenstam (1998)
Dose–response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancerEuropean Journal of Cancer, 34
I. Tannock, N. Boyd, G. Deboer, C. Erlichman, S. Fine, G. Larocque, C. Mayers, D. Perrault, H. Sutherland (1988)
A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 6 9
W. Evans, M. Relling, J. Rodman, W. Crom, J. Boyett, C. Pui (1998)
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.The New England journal of medicine, 338 8
D. Bois, E. Bois (1916)
A formula to estimate the approximate surface area if height and weight be knownArch Intern Med, 17
J. Bergh, T. Wiklund, B. Erikstein, E. Lidbrink, H. Lindman, P. Malmström, P. Kellokumpu-Lehtinen, N. Bengtsson, Gustaf Söderlund, G. Anker, E. Wist, Susanne Ottosson, E. Salminen, P. Ljungman, H. Holte, J. Nilsson, C. Blomqvist, N. Wilking (2000)
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trialThe Lancet, 356
M. Piccart, C. Lohrisch, L. Duchateau, M. Buyse (2001)
Taxanes in the adjuvant treatment of breast cancer: why not yet?Journal of the National Cancer Institute. Monographs, 30
B. Fisher, S. Anderson, D. Wickerham, A. DeCillis, N. Dimitrov, E. Mamounas, N. Wolmark, R. Pugh, J. Atkins, F. Meyers, N. Abramson, J. Wolter, R. Bornstein, L. Levy, E. Romond, V. Caggiano, M. Grimaldi, P. Jochimsen, P. Deckers (1997)
Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 5
H. Gurney (1996)
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 9
Gehan Ea, S. George (1970)
Estimation of human body surface area from height and weight.Cancer chemotherapy reports, 54 4
J. Bergh (2000)
Where next with stem-cell-supported high-dose therapy for breast cancer? [comment]Lancet, 355
M. Clarke, R. Collins, C. Davies, J. Godwin, R. Gray, R. Peto (1998)
Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 352
C. Redmond, B. Fisher, Wieand Hs (1983)
The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival.Cancer treatment reports, 67 6
D. Dubois, Dunne Ef (1989)
A formula to estimate the approximate surface area if height and weight be knownJAMA Internal Medicine, 17
J. Bergh, P. Jönsson, B. Glimelius, P. Nygren (2001)
A systematic overview of chemotherapy effects in breast cancer.Acta oncologica, 40 2-3
D. Bois, E. Bois (1916)
CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWNJAMA Internal Medicine, 17
M. Sandström, A. Freijs, R. Larsson, P. Nygren, M. Fjällskog, J. Bergh, M. Karlsson (1996)
Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 5
(1992)
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.Lancet, 339 8785
W. Peters, G. Rosner, J. Vredenburgh (1999)
A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (In): preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13 [abstract 2]
W. Peters, E. Shpall, R. Jones, G. Olsen, R. Bast, J. Gockerman, J. Moore (1988)
High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 6 9
W. Wood, D. Budman, A. Korzun, M. Cooper, J. Younger, R. Hart, A. Moore, J. Ellerton, L. Norton, C. Ferree, A. Ballow, E. Frei, I. Henderson (1994)
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.The New England journal of medicine, 330 18
(1998)
Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 351
B. Fisher, Stewart Anderson, A. DeCillis, N. Dimitrov, J. Atkins, L. Fehrenbacher, Patrick Henry, E. Romond, K. Lanier, Enrique Davila, C. Kardinal, Leslie Laufman, H. Pierce, Neil Abramson, Alan Keller, John Hamm, D. Wickerham, Mirsada Begovic, E. Tan-chiu, Wei Tian, N. Wolmark (1999)
Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 11
R. Fossati, C. Confalonieri, V. Torri, E. Ghislandi, A. Penna, V. Pistotti, A. Tinazzi, A. Liberati (1998)
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 10
W. Dawson (1940)
RELATIONS BETWEEN AGE AND WEIGHT AND DOSAGE OF DRUGSAnnals of Internal Medicine, 13
M. Moore, C. Erlichman, J. Thiessen, P. Bunting, R. Hardy, I. Kerr, S. Soldin (2004)
Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancerCancer Chemotherapy and Pharmacology, 33
T. Saarto, Carl Blomqvist, P. Rissanen, Anssi Auvinen, I. Elomaa (1997)
Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer.British Journal of Cancer, 75
Standard adjuvant polychemotherapy for patients with breast cancer significantly improves their survival and is used for this patient group worldwide. In the beginning of this era, mainly CMF (cyclophosphamide, methotrexate and fluorouracil) was used but CMF is nowadays often replaced by anthracycline containing regimens after results favoring anthracyclines were published. The role of taxanes in the adjuvant setting is not yet fully understood; however, this should become clearer following the results from several ongoing randomized studies. In addition to the question of which drugs to use, dosage recommendations are a more complex issue. Low dosage regimens have been associated with inferior survival results compared with standard dosages in the adjuvant setting. High dosage regimens of anthracyclines have not been associated with better survival in some studies, although some investigators have shown the opposite. The use of very high doses requiring autologous bone marrow support have not resulted in survival gains in randomized studies.
American Journal of Cancer – Springer Journals
Published: Aug 9, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.